At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Lithium Carbonate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)
In Brief
A Phase 2 clinical trial evaluating Lithium Carbonate and Prophylactic cranial irradiation for Small Cell Lung Carcinoma. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This treatment can cause short-term memory problems by damaging the hippocampus. Lithium may help prevent or lessen memory problems caused by PCI by protecting the hippocampus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionSep 2016
Study CompletionJun 2017
TodayJul 2026
First PostedMar 14, 2012
Enrollment StartApr 26, 2012
Primary CompletionSep 12, 2016
Study CompletionJun 5, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 14.3 years ago
Interventions
Lithium Carbonatedrug
Prophylactic cranial irradiationradiation